Kordbacheh Hamed, Ristic Gorica, Heath Elisabeth, Kim Seongho, Raza Kumayl, Heilbrun Lance, Aoun Hussein D
Karmanos Cancer Institute, Wayne State University, Detroit, USA.
Detroit Medical Center, Detroit, USA.
Abdom Radiol (NY). 2025 Apr 7. doi: 10.1007/s00261-025-04918-8.
To assess the overall concordance of a fast prostate MRI (fpMRI) protocol versus conventional multiparametric prostate MRI (mpMRI) protocol.
This is an IRB approved retrospective review of 100 men between the ages of 50 and 80 who underwent mpMRI exams from January 2016 to May 2021. The mpMRI exams selected came from three categories: Group A (PI-RADS 1-2); Group B (PI-RADS 3); and Group C (PI-RADS 4-5). Two masked radiologists independently reviewed and assigned each fpMRI case the highest possible lesion PI-RADS score. The collected fpMRI scores were then compared to the mpMRI results, PSA values, and available targeted biopsy outcomes.
The concordance rates between the two fpMRI reviewers and mpMRI for the individually assessed groups (A, B, C) were 0.69 (95% CI,0.62 to 0.75). The PPV of groups B or C combined for GS ≥ 7 for mpMRI, R1 fpMRI, and R2 fpMRI was 62% (40/64; 95% CI,0.50 to 0.74), 67% (40/60; 95% CI,0.53 to 0.78), and 72% (39/54; 95% CI,0.58 to 0.84), respectively. The negative predictive value (NPV) of group B or C combined for GS ≥ 7 on mpMRI, R1 fpMRI, and R2 fpMRI was 100% (3/3; 95% CI,29 to 100%), 100% (7/7; 95% CI,59 to 100%), and 92% (12/13; 95% CI,64 to 100%), respectively.
The concordance rates, PPV and NPV between the mpMRI and fpMRI results for groups B and C were moderately high, moderately high, and very high, respectively. This pilot study suggests that a larger prospective study might be beneficial to help establish fpMRI as a screening tool for prostate cancer.
评估快速前列腺MRI(fpMRI)方案与传统多参数前列腺MRI(mpMRI)方案的总体一致性。
这是一项经机构审查委员会(IRB)批准的回顾性研究,对2016年1月至2021年5月期间接受mpMRI检查的100名年龄在50至80岁之间的男性进行了研究。所选的mpMRI检查来自三类:A组(前列腺影像报告和数据系统(PI-RADS)1-2级);B组(PI-RADS 3级);C组(PI-RADS 4-5级)。两名盲法放射科医生独立审查并为每个fpMRI病例分配尽可能高的病变PI-RADS评分。然后将收集到的fpMRI评分与mpMRI结果、前列腺特异性抗原(PSA)值以及可用的靶向活检结果进行比较。
在对各个评估组(A、B、C)进行评估时,两名fpMRI审查员与mpMRI之间的一致性率为0.69(95%置信区间,0.62至0.75)。对于mpMRI、R1 fpMRI和R2 fpMRI,B组或C组合并后GS≥7的阳性预测值(PPV)分别为62%(40/64;95%置信区间,0.50至0.74)、67%(40/60;95%置信区间,0.53至0.78)和72%(39/54;95%置信区间,0.58至0.84)。对于mpMRI、R1 fpMRI和R2 fpMRI,B组或C组合并后GS≥7的阴性预测值(NPV)分别为100%(3/3;95%置信区间,29至100%)、100%(7/7;95%置信区间,59至100%)和92%(12/13;95%置信区间,64至100%)。
B组和C组的mpMRI与fpMRI结果之间的一致性率、PPV和NPV分别为中等偏高、中等偏高和非常高。这项初步研究表明,开展一项更大规模的前瞻性研究可能有助于将fpMRI确立为前列腺癌的筛查工具。